Audit: QRS - Microdosing MDMA for Health & Longevity
Audit conducted on 22/09/2026 18:40 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 85 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every cell traces to ER text: protocol cells to Therapeutic Protocol, gates to Key Interactions & Contraindications, tiers to Expected Benefits / Potential Risks & Side Effects, markers and cadence to Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No validated dosing protocol exists”, “No established time course”, “(conflicted)” on both ER ⚠️ Conflicted items, “Claimed cumulative benefits” all preserved. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Absolute avoidance items stay in Contraindications; relative avoidance is explicitly flagged “Relative:”; conflicted markers retained. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or risk tiers. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, author names, or brand names anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sober, evidence-skeptical register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents thresholds, targets, and trackable markers rather than prohibitions in the sheet’s own voice. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol and monitoring cells state what is done and measured, not what the reader must do. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must”, or prescriptive second-person construction in QRS content. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Descriptive throughout (e.g. “Single morning dose”, “No validated dosing protocol exists”). |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns in any variable span. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are either ER-sourced and audience-appropriate or glossed (e.g. “Echocardiogram (ultrasound of the heart)”, “eGFR (estimated glomerular filtration rate)”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, tier lines, and marker rows are single clauses; multi-paragraph ER content is reduced to phrase level. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you”/”your” occurrences. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes genotyping, echocardiography, and self-tracking capability. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Cadence includes pre/post-dose blood pressure, serial labs, and annual echocardiography. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional target ranges are tighter than conventional reference ranges, as in the ER. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Emphasis on cumulative sympathetic load, escalation signals, and CYP2D6 status is audience-specific. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”; the title uses “Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | “oral dose”, “synthetic compound”, “supervised therapy”, “serotonergic” — no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate heads, tier labels, and column headers byte-identical to the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 35 distinct template variables present; marker_#* expanded to 9 rows and qualitative_item# to 6 items. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against the template shows only the sanctioned changes: the display: none on [benefits_high] (item 12.5) and repeated marker/qualitative rows. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the empty benefits High tier is governed by item 12.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Best time of day”, “Half-life and its practical implication”, and all six Qualitative Assessment labels are verbatim ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Only the trailing em-dash attribution clause is dropped from “The community microdosing schedule — Fadiman’s framework, applied by analogy”; no label is reworded or invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the file; the ER’s ⚠️ Conflicted marker is rendered as plain “(conflicted)”. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to phrase level against its per-section budget; no section carries ER prose, magnitudes, or mechanistic detail. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: microdosing_mdma_2026-0805-0248_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.22 matches the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0922-1808. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: microdosing_mdma_2026-0805-0248_Opus_QRS.html matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Microdosing MDMA for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Microdosing MDMA for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0922-1808 → “09/22/2026”. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “MDMA is a synthetic compound, known illicitly as ecstasy, used in supervised therapy for severe trauma; microdosing means repeating amounts too small to be felt…” before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Carries the Conclusion’s three load-bearing points: untested practice, well-characterized short-term burden, benefits reported not demonstrated. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 67 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Traces to Motivation (what it is / why used) and Conclusion (untested, pressor and memory effects, antidepressant danger, reported-not-demonstrated). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Only the intervention’s own name; “blood pressure”, “heart rate”, “memory”, “antidepressants” are lay terms. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial references. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the “Populations who should avoid this intervention” bullet. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 11 absolute-avoidance conditions plus the three relative-avoidance conditions, as 12 list items. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | 12 <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes or trailing clauses; ER glosses (“a scoring system for how badly liver function is compromised”) are stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | 14-day MAOI washout, 160/100 mmHg, “moderate or greater”, 12 months, Child-Pugh B or C, 30 mL/min/1.73 m², bipolar I / first-degree relative, six weeks all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names an extensive avoidance list, and the section is correctly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Maps one-to-one onto the ER’s seven caution bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | MAOIs and the avoidance populations are in Contraindications and are not repeated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | 7 <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “— caution, with a dual problem” style trailing clauses and all mechanism sentences are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named drug lists retained for all seven items (SSRIs/SNRIs, CYP2D6 inhibitors, other serotonergics, OTC agents, serotonergic supplements, stimulant supplements, co-interventions). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names seven interaction classes, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to Therapeutic Protocol bullets. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Amount (5 to 25 mg), timing (morning), and frequency (no more than weekly) — the three decisions the ER’s protocol section actually resolves. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields populated from ER text; the absence of a validated protocol is carried in action_1_sub. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Acute onset, acute peak, and claimed cumulative benefits — the three distinct time courses in the ER’s “Time to effect” bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | The Medium-tier acute lift (onset, then peak) precedes the Low/Speculative cumulative claims. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; values 30–60 minutes, 90–120 minutes, and “No established time course” are ER-literal. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides a dedicated “Time to effect” bullet in Practical Considerations. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Each tier line lists the ER subsection headings for that tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; no Magnitude text, oxytocin mechanism, or study description carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Nothing parenthetical survives except the ER’s own “Conflicted” evidence flag, whose retention is required by items 1.2 and 1.3. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER’s empty High tier is handled with style="display: none" and an empty span. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All 16 ER risk subsections are represented across the four tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | No odds ratios, confidence intervals, mg/kg thresholds, or mechanism sentences carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Nothing parenthetical survives except the ER’s “Conflicted” flag on serotonergic neurotoxicity, required by items 1.2 and 1.3. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items; no tier is empty. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows taken from the biomarker table in Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER rows present: blood pressure, heart rate, serum sodium, ALT, GGT, eGFR, hs-CRP, echocardiogram, CYP2D6 genotype — with ER target ranges intact. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Reproduces the ER cadence paragraph, including the echocardiography trigger conditions. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the qualitative marker bullets. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present with verbatim ER bold labels: sleep quality, mood trajectory, cognitive clarity and work output, social engagement, physical side-effect burden, escalation signals. |
Issues 22/09/2026 18:40
Pass rate 100.00%. No issues found.
Issues 22/09/2026 18:32
- 1.3 — Hedge dropped from time-to-effect note: [time_3_sub] (QRS line 511) states “in other compounds self-reported benefit appears within two weeks”, while the ER
Practical Considerationsbullet only says the microdosing literature on other compounds “suggests” that benefit appears within the first two weeks.
Fixes 22/09/2026 18:32
- 1.3 — Hedge restored in time-to-effect note: [time_3_sub] changed from “in other compounds self-reported benefit appears within two weeks” to “in other compounds self-reported benefit is suggested within two weeks”, matching the ER’s hedged phrasing.
Issues 22/09/2026 18:22
- 4.5 — Content overruns one A4 page: The sheet carries full ER sentences in the protocol/time sub-cells, monitoring “Why” cells, the 89-word cadence paragraph (line 707) and all six qualitative items, alongside a 12-item Contraindications gate (lines 540–551); the combined flow is roughly two A4 pages rather than one.
Fixes 22/09/2026 18:22
- 4.5 — Condensed to the one-page budget: Every over-long region was tightened while keeping all required items: the six protocol and time-to-effect sub-cells were shortened, the benefit and risk tier lists trimmed to bare key facts, the twelve Contraindications and seven Key Interactions reworded to one or two lines each (all thresholds, time windows and example drug lists preserved), seven monitoring “Why” cells and the echocardiogram marker name shortened, the cadence paragraph cut from 89 to 74 words, and four qualitative items reduced to their core measurement.
Issues 22/09/2026 18:14
- 4.2 / 4.3 — Invented Protocol cell label: [action_3_label] at line 466 reads “Dosing frequency”, which is not an ER bold label; the cell’s content derives from the ER
Therapeutic Protocolbullet “Half-life and its practical implication:” (ER line 436), and the other Protocol cells do use ER labels verbatim.
Fixes 22/09/2026 18:14
- 4.2 / 4.3 — Protocol cell label taken from ER: Replaced the invented [action_3_label] “Dosing frequency” with the ER’s verbatim bold label “Half-life and its practical implication” (ER line 436), the bullet the cell’s value and sub-text are drawn from.